Over 15 million people worldwide die each year of infectious diseases. Vaccines to prevent these diseases represent the most cost-effective solutions to improving global health. Inviragen, Inc. is committed to developing safe, effective vaccines to address this need.

Inviragen is focused on developing life-saving vaccines to protect against emerging infectious diseases worldwide. Inviragen's lead product is a vaccine to protect against dengue fever, a disease that threatens 2.5 billion people across the globe. Inviragen is also developing a vaccine to protect against West Nile for the North American market, a nasal combination vaccine to protect against both plague and smallpox for biodefense, and a unique vaccine to protect against avian influenza for global markets.